MCID: HRD009
MIFTS: 40

Hereditary Wilms' Tumor

Categories: Cancer diseases, Nephrological diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Hereditary Wilms' Tumor

MalaCards integrated aliases for Hereditary Wilms' Tumor:

Name: Hereditary Wilms' Tumor 12 14 69
Hereditary Wilms Tumor 12
Wt1 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5183
NCIt 47 C8496
UMLS 69 C0677779

Summaries for Hereditary Wilms' Tumor

Disease Ontology : 12 A nephroblastoma that results_in either bilateral disease or a family history of Wilms' tumour.

MalaCards based summary : Hereditary Wilms' Tumor, also known as hereditary wilms tumor, is related to wilms tumor susceptibility-5 and frasier syndrome, and has symptoms including abdominal pain An important gene associated with Hereditary Wilms' Tumor is WT1 (Wilms Tumor 1), and among its related pathways/superpathways are Akt Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Itraconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and bone marrow, and related phenotypes are Apoptosis resistance and mortality/aging

Related Diseases for Hereditary Wilms' Tumor

Diseases in the Familial Wilms Tumor family:

Wilms Tumor 6 Wilms Tumor 2
Hereditary Wilms' Tumor Familial Wilms Tumor 2

Diseases related to Hereditary Wilms' Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
id Related Disease Score Top Affiliating Genes
1 wilms tumor susceptibility-5 11.9
2 frasier syndrome 11.8
3 denys-drash syndrome 11.8
4 nephrotic syndrome, type 4 11.3
5 meacham syndrome 11.2
6 nephrotic syndrome 11.2
7 myeloid leukemia 11.2
8 myelodysplastic syndrome 11.2
9 acute leukemia 11.2
10 focal segmental glomerulosclerosis 11.2
11 wagr syndrome 11.2
12 diffuse mesangial sclerosis 11.2
13 desmoplastic small round cell tumor 11.1
14 kidney disease 11.1
15 aniridia 11.1
16 ewing sarcoma 11.1
17 congenital diaphragmatic hernia 11.1
18 hypospadias 11.1
19 pseudohermaphroditism 11.1
20 clear cell sarcoma 11.1
21 congenital mesoblastic nephroma 11.1
22 adenomatoid tumor 11.1
23 malignant pleural mesothelioma 11.1
24 gonadal dysgenesis 11.0
25 gonadoblastoma 11.0
26 renal cell carcinoma 11.0
27 sertoli cell tumor 11.0
28 ovarian serous carcinoma 11.0
29 crescentic glomerulonephritis 11.0
30 peritoneal mesothelioma 11.0
31 cytogenetically normal acute myeloid leukemia 11.0
32 cryptorchidism 10.9
33 uterine sarcoma 10.9
34 caudal regression syndrome 10.9
35 46 xy gonadal dysgenesis 10.9
36 cerebellar angioblastoma 10.9
37 hemihypertrophy 10.9
38 familial wilms tumor 10.9
39 core binding factor acute myeloid leukemia 10.9
40 chronic eosinophilic leukemia 10.9
41 renal cell carcinoma, papillary 10.8
42 meacham winn culler syndrome 10.8
43 mesothelioma, somatic 10.8
44 sex cord-gonadal stromal tumor 10.7
45 leiomyosarcoma 10.7
46 kidney cancer 10.7
47 benign mesothelioma 10.7
48 rhabdomyosarcoma 2, alveolar 10.7
49 ovarian cancer, somatic 10.7
50 premature ovarian failure 1 10.7

Graphical network of the top 20 diseases related to Hereditary Wilms' Tumor:



Diseases related to Hereditary Wilms' Tumor

Symptoms & Phenotypes for Hereditary Wilms' Tumor

UMLS symptoms related to Hereditary Wilms' Tumor:


abdominal pain

GenomeRNAi Phenotypes related to Hereditary Wilms' Tumor according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Apoptosis resistance GR00093-A-0 8.92 PPP2R1A PPP2R1B PPP6C PTPA

MGI Mouse Phenotypes related to Hereditary Wilms' Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10 ALK CDC73 HRAS IGF2 PAX6 PHOX2B
2 growth/size/body region MP:0005378 9.97 ALK CDC73 HRAS IGF2 PAX6 PHOX2B
3 embryo MP:0005380 9.91 CDC73 IGF2 PAX6 PHOX2B PPP6C REST
4 neoplasm MP:0002006 9.63 ALK HRAS PAX6 PPP2R1A PPP6C WT1
5 reproductive system MP:0005389 9.43 REST WT1 ALK CDC73 IGF2 PAX6
6 respiratory system MP:0005388 9.17 WT1 ALK CDC73 HRAS IGF2 PAX6

Drugs & Therapeutics for Hereditary Wilms' Tumor

Drugs for Hereditary Wilms' Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
3 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
4 Antifungal Agents Phase 4,Phase 2,Phase 1
5 Cytochrome P-450 CYP3A Inhibitors Phase 4
6 Cytochrome P-450 Enzyme Inhibitors Phase 4
7 Hormone Antagonists Phase 4,Phase 2,Phase 1
8 Hormones Phase 4,Phase 2,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
10 Hydroxyitraconazole Phase 4
11 Steroid Synthesis Inhibitors Phase 4
12
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
13
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
14
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
15
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
16
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
17
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
18
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
19
Sulfamethoxazole Approved Phase 3 723-46-6 5329
20
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
21
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
27 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Etoposide phosphate Phase 3,Phase 2,Phase 1
30 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
31 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
32 Adjuvants, Immunologic Phase 3,Phase 1
33 Liver Extracts Phase 3,Phase 2
34
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
35
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Ifosfamide Approved Phase 2,Phase 1 3778-73-2 3690
38
Mechlorethamine Approved Phase 2,Phase 1 51-75-2 4033
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40 Thiotepa Approved Phase 2 52-24-4 5453
41
Olaparib Approved Phase 2 763113-22-0 23725625
42
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
43
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
44
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
46
Adenosine Approved, Investigational Phase 2 58-61-7 60961
47
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
50
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936

Interventional clinical trials:

(show top 50) (show all 81)

id Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Collaborative Wilms Tumour Africa Project Recruiting NCT01991652 Phase 4
3 Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor Unknown status NCT00003804 Phase 3 vincristine sulfate
4 Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
5 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed NCT00379340 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;cyclophosphamide;etoposide
6 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed NCT00352534 Phase 3 vincristine sulfate;doxorubicin hydrochloride
7 Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed NCT00002610 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
8 Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed NCT00002611 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
9 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Active, not recruiting NCT00945009 Phase 3 Doxorubicin Hydrochloride;Vincristine Sulfate;Carboplatin;Cyclophosphamide;Etoposide Phosphate
10 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
11 Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney Unknown status NCT00025103 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;melphalan;vincristine sulfate
12 A Phase II Study of Topotecan in Children With Recurrent Wilms Tumor Completed NCT00187031 Phase 2 Topotecan, Filgrastim (G-CSF), Pegfilgrastim
13 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Completed NCT00433745 Phase 2 WT1 Peptide Vaccine
14 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2 sorafenib tosylate
15 A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor Completed NCT00001509 Phase 2 IFN-alpha with retinoic acid
16 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
17 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2 Doxorubicin Hydrochloride;Irinotecan Hydrochloride;Cyclophosphamide;Etoposide;Carboplatin;Vincristine Sulfate
18 Pharmacokinetic Study of Doxorubicin in Children With Cancer Completed NCT01095926 Phase 2 doxorubicin
19 Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2 Liposomal Vincristine
20 To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Completed NCT01222780 Phase 1, Phase 2 Marqibo
21 Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers Completed NCT00141765 Phase 2
22 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
23 Ixabepilone in Treating Young Patients With Refractory Solid Tumors Completed NCT00331643 Phase 2 ixabepilone
24 Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Recruiting NCT02581384 Phase 1, Phase 2
25 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
26 Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
27 Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations Recruiting NCT03213665 Phase 2 Tazemetostat
28 Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
29 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
30 Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
31 Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib
32 Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting NCT02624388 Phase 2 Genistein;Placebo
33 Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Recruiting NCT02689336 Phase 2 Temozolomide
34 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
35 A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation Active, not recruiting NCT00405327 Phase 2
36 Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations Not yet recruiting NCT03210714 Phase 2 Erdafitinib
37 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Completed NCT01169584 Phase 1 Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
38 Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides Completed NCT01598454 Phase 1 racotumomab
39 Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors Completed NCT00011414 Phase 1 Tariquidar
40 Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer Completed NCT01445379 Phase 1 Ipilimumab
41 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin
42 A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Recruiting NCT02536183 Phase 1 Lyso-thermosensitive liposomal doxorubicin
43 ODSH + ICE Chemotherapy in Pediatric Solid Tumors Recruiting NCT02164097 Phase 1 ODSH
44 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Recruiting NCT02982941 Phase 1 Enoblituzumab
45 MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Recruiting NCT02076906 Phase 1
46 HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Recruiting NCT00931931 Phase 1
47 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
48 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
49 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting NCT01625351 Phase 1 alemtuzumab;fludarabine;sirolimus;Busulfan;melphalan
50 RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia Withdrawn NCT01236586 Phase 1 RO4929097;Dexamethasone

Search NIH Clinical Center for Hereditary Wilms' Tumor

Genetic Tests for Hereditary Wilms' Tumor

Anatomical Context for Hereditary Wilms' Tumor

MalaCards organs/tissues related to Hereditary Wilms' Tumor:

39
Kidney, Bone, Bone Marrow, Liver, Myeloid, T Cells, Testes

Publications for Hereditary Wilms' Tumor

Variations for Hereditary Wilms' Tumor

Expression for Hereditary Wilms' Tumor

Search GEO for disease gene expression data for Hereditary Wilms' Tumor.

Pathways for Hereditary Wilms' Tumor

Pathways related to Hereditary Wilms' Tumor according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 ALK HRAS IGF2 PPP2R1A PPP2R1B PTPA
2
Show member pathways
13.04 ALK HRAS IGF2 PPP2R1A PPP2R1B PTPA
3
Show member pathways
12.61 ALK HRAS IGF2 PPP2R1A PPP2R1B PTPA
4
Show member pathways
12.45 HRAS PPP2R1A PPP2R1B PTPA
5
Show member pathways
12.34 HRAS PPP2R1A PPP2R1B PTPA
6 12.26 CDC73 CDKN1C PPP2R1A PTPA
7
Show member pathways
12.08 CDKN1C PPP2R1A PPP2R1B PTPA
8
Show member pathways
11.99 PPP2R1A PPP2R1B PTPA
9 11.89 HRAS PAX6 REST
10 11.85 HRAS PPP2R1A PPP2R1B
11 11.78 HRAS PPP2R1A PPP2R1B
12
Show member pathways
11.61 PPP2R1A PPP2R1B PTPA
13 11.48 PPP2R1A PPP2R1B PTPA
14 11.46 HRAS PPP2R1A PPP2R1B PTPA
15
Show member pathways
11.39 HRAS PPP2R1A PPP2R1B
16 11.32 HRAS PPP2R1A PPP2R1B
17 11.22 PPP2R1A PPP2R1B PTPA
18
Show member pathways
11.01 HRAS PPP2R1A PPP2R1B PTPA
19
Show member pathways
11 HRAS IGF2
20 10.69 PPP2R1A PPP2R1B PTPA

GO Terms for Hereditary Wilms' Tumor

Cellular components related to Hereditary Wilms' Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase type 2A complex GO:0000159 8.62 PPP2R1A PTPA

Biological processes related to Hereditary Wilms' Tumor according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.91 CDC73 HRAS PAX6 PHOX2B REST WT1
2 transcription from RNA polymerase II promoter GO:0006366 9.8 CDC73 PAX6 PHOX2B REST WT1
3 camera-type eye development GO:0043010 9.54 CDKN1C PAX6 WT1
4 negative regulation of epithelial cell proliferation GO:0050680 9.5 CDC73 CDKN1C PAX6
5 adrenal gland development GO:0030325 9.49 CDKN1C WT1
6 negative regulation of neurogenesis GO:0050768 9.48 PAX6 REST
7 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001241 9.46 PPP2R1A PPP2R1B
8 negative regulation of neuron differentiation GO:0045665 9.33 PAX6 PHOX2B REST
9 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.26 CDC73 CDKN1C REST WT1
10 negative regulation of cell proliferation GO:0008285 9.1 CDC73 HRAS PAX6 PHOX2B REST WT1
11 embryonic placenta morphogenesis GO:0060669 8.96 CDKN1C

Sources for Hereditary Wilms' Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....